Breaking News

Financial Report: PDL BioPharma

May 10, 2013

Royalty revenues up 19% in the quarter

PDL BioPharma

1Q Revenues: $91.8 million (+19%)

1Q Earnings: $53.5 million (+33%)

Comments: Royalty revenues were up 19% driven by increased royalties from Avastin, Herceptin, Lucentis, Tysabri, and Actemra.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks